<code id='29F536272E'></code><style id='29F536272E'></style>
    • <acronym id='29F536272E'></acronym>
      <center id='29F536272E'><center id='29F536272E'><tfoot id='29F536272E'></tfoot></center><abbr id='29F536272E'><dir id='29F536272E'><tfoot id='29F536272E'></tfoot><noframes id='29F536272E'>

    • <optgroup id='29F536272E'><strike id='29F536272E'><sup id='29F536272E'></sup></strike><code id='29F536272E'></code></optgroup>
        1. <b id='29F536272E'><label id='29F536272E'><select id='29F536272E'><dt id='29F536272E'><span id='29F536272E'></span></dt></select></label></b><u id='29F536272E'></u>
          <i id='29F536272E'><strike id='29F536272E'><tt id='29F536272E'><pre id='29F536272E'></pre></tt></strike></i>

          fashion

          fashion

          author:focus    Page View:391
          Fiona Marshall, president of the Novartis research hub in Cambridge, Mass., speaks Thursday during the STAT Future Summit. STAT

          Swiss drugmaker Novartis’ research and development hub has a new name — and a new guiding strategy.

          The hub, which is headquartered in Cambridge, Mass., and for years has been known as Novartis Institutes for BioMedical Research, or NIBR, will soon simply be known as Novartis Biomedical Research.

          advertisement

          But that’s not the only thing that’s changing, Fiona Marshall, the hub’s president, told a virtual audience Thursday during the 2023 STAT Future Summit. The new name reflects a larger shift by the pharma giant to retool its research strategy — from one driven by the pure pursuit of scientific discovery to a tighter focus on projects likely to yield commercially successful drugs.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          explore

          In Memoriam: Notable people who died in 2023
          In Memoriam: Notable people who died in 2023

          1:29AlanArkinattendsthe26thAnnualScreenActorsGuildAwardsatTheShrineAuditoriumonJan.19,2020inLosAngel

          read more
          FDA approves Recor Medical high blood pressure device
          FDA approves Recor Medical high blood pressure device

          ReCorMedical,astartupownedbyJapanesecompanyOtsukaMedicalDevices,andMedtronichaverunstudiesthatshowed

          read more
          Novavax promises a turnaround & Lilly roils the obesity market
          Novavax promises a turnaround & Lilly roils the obesity market

          SammyKimballforSTATCanNovavaxfinallygetitright?What’sa“triple-G”drug?AndisNovoNordisklosingground?We

          read more

          Element Biosciences CEO lays out genome sequencing strategy

          ElementBiosciencesexteriorElementBiosciencesSANDIEGO—Companiesracingtoreadthegenomeaccurately,quickl